Get started Log in

CDAKQ — Codiak BioSciences,. Share News

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro Cap

Market Cap
$0.06m
Enterprise Value
-$26.01m
Revenue
$22.94m

U.S. RESEARCH ROUNDUP-Crowdstrike, LPL Financial, Signify Health
31/08/2022 19:04
U.S. RESEARCH ROUNDUP-Crowdstrike Holdings, LPL Financial Holdings, Signify Health
31/08/2022 08:03
Codiak up on restructuring plans
30/08/2022 18:43
Brief: Codiak Biosciences Reports Second Quarter 2022 Financial Results And Operational Progress
04/08/2022 21:50
Brief: CEPI And Codiak BioSciences Partner To Develop Broadly Protective Betacoronavirus Vaccine
05/07/2022 12:58
Brief: Codiak Provides Platform-Validating Clinical Update And Data From Phase 1 Trials Of Exosting And Exoil-12
30/06/2022 11:34
Brief: Codiak Initiates Patient Dosing In Phase 1 Clinical Trial Of Exoaso-Stat6 In Patients With Advanced Hepatocellular Carcinoma, Liver Metastases From Primary Gastric Cancer And Colorectal Cancer
29/06/2022 13:03
Codiak BioSciences, Inc. reports results for the quarter ended in March - Earnings Summary
06/05/2022 05:55
Brief: Codiak Biosciences Reports First Quarter 2022 Financial Results
05/05/2022 23:22
Codiak BioSciences, Inc. expected to post a loss of 89 cents a share - Earnings Preview
02/05/2022 18:01
Brief: Codiak Presents New Preclinical Data Supporting Development Of A Broadly Protective Pan Beta-Coronavirus Vaccine
20/04/2022 22:01
Codiak BioSciences, Inc. reports results for the quarter ended in December - Earnings Summary
15/03/2022 13:32
Brief: Codiak Biosciences Reports Fourth Quarter And Full Year 2021 Financial Results And Recent Operational Progress
10/03/2022 21:05
Brief: Sporos Bioventures Announces Formation Of Strategic Advisory Board
11/01/2022 14:33
Brief: Codiak’S Engineered Exosomes Promote T Cell And Antibody Responses To Sars-Cov-2 In Vivo, Supporting The Potential For A Broadly Protective Pan-Beta Coronavirus And Variant Vaccine
02/12/2021 13:41
Brief: Codiak Biosciences Announces FDA Clearance Of IND For exoASO™-Stat6 Patient Dosing Expected 1H 2022
30/11/2021 14:01
Brief: Codiak Reports Positive Initial Data From Phase 1/2 Trial Of Exosting™ Indicating Evidence Of Tumor Shrinkage
16/11/2021 11:55
Brief: Codiak Biosciences Files For Mixed Shelf Of Up To $300 Million – SEC Filing
04/11/2021 21:53
Brief: Lonza To Acquire Codiak Biosciences Exosomes Manufacturing Facility
02/11/2021 13:05
Brief: Codiak Says Sarepta Notified It Was Terminating Early Research License & Option Deal
07/10/2021 22:13